MedinCell CEO on Long-Acting Drugs & France’s $1B Biotech Club | Christophe Douat | E62

Christophe has run MedinCell since 2009, when it was eight people in a converted garage. Today it's one of only three French biotechs to ever cross $1B on Euronext.With one Teva-partnered product already a commercial success, the partners are potentially weeks away from getting FDA approval for a second.We also talked about France’s biotech giants, the landscape of long-acting injectables, and why Christophe was once in charge of a remote fishing lodge in Canada.---Discover the best biotech companies in 🇪🇺 with the FlotBio Map at bit.ly/4nXmKjN---
⭐️ ABOUT THE SPEAKER
Before his time as CEO of MedinCell, Christophe was lead investor in Nanobiotix and served in roles at the Boston Consulting Group, and Matignon Investissement & Gestion.He also spent 15 years in North America, and he holds an engineering degree from École des Mines de Paris, a Master’s degree from the University of Minnesota, and an MBA from the University of Calgary.
🔗 LINKS MENTIONED
• Christophe Douat LinkedIn profile — linkedin.com/in/christophe-douat-16268a
• MedinCell — medincell.com
• Teva — tevapharm.com
• Uzedy FDA approval, April 2023 — tevausa.com/news-and-media/press-releases/teva…
• MedinCell investor presentation, Sept 2026 — medincell.com/wp-content/uploads/2026/09/Inves…
• Pascal Touchon, Flot.bio E49 — flot.bio/episode/pascal-touchon-jeito
• Fredrik Tiberg, Flot.Bio E51 (Camurus) — flot.bio/episode/fredrik-tiberg-camurus-opioid…
• Laurent Levy, Flot.Bio E45 (Nanobiotix) — flot.bio/episode/laurent-levy-nanobiotix-nanop…
• Marc de Garidel, Flot.Bio E46 (Abivax) — flot.bio/episode/marc-de-garidel-abivax-ulcera…
• Michel Vert, University of Montpellier — ibmm.umontpellier.fr/en/annuaire/vert-michel-2
• Teva completes Actavis Generics acquisition, 2016 — ir.tevapharm.com/news-and-events/press-release…
• J&J acquires Intra-Cellular Therapies, $14.6B — jnj.com/media-center/press-releases/johnson-jo…
📜 TRANSCRIPTRead the full transcript here: flot.bio/episode/medincell-french-biotech-giants
💸 DONATE
We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: paypal.me/PhilipHemme
⭐️ SPONSORSHIP
Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!
🫶 FOLLOW US
• Newsletter: eepurl.com/h_fnmH
• LinkedIn: linkedin.com/company/flot-bio
• X (Twitter): x.com/FlotBio
🙏 LIKE/FOLLOW/REVIEW
Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.
🎙️ ABOUT FLOT.BIO
Flot.Bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free.
⏰ TIMESTAMPS
• [00:00:00] Intro
• [00:03:05] Jeito’s Pascal Touchon: a Mutual Friend
• [00:05:35] Uzedy and Long-Acting Injectable Olanzapine: the Commercial Drive
• [00:07:42] How MedinCell Could Succeed with Olanzapine LAI Where Eli Lilly Failed
• [00:16:57] Camurus and MedinCell: European Champions in Long-Acting Injectables
• [00:20:51] Montpellier and the Foundation of MedinCell
• [00:25:19] Teva Pharmaceuticals: an Agile Partner
• [00:30:08] Nanobiotix and France’s $1B Market Cap Club
• [00:36:39] Contraception, Malaria and Schizophrenia: the Human Factor
• [00:46:05] From a Fishing Lodge in Ontario to Biotech CEO
• [00:51:10] Quick-Fire Questions